CL2008002652A1 - Uso de un compuesto inhibidor de esfingosina-1-fosfato (s1p) liasa derivado de imidazol -etiloxima,-hidrazida, -sulfonohidrazid o -carboxamida y un inmunosupresor para tratar o prevenir un trastorno inunologico o inflamatorio; y composicion farmaceutica que comprende dicho compuesto y un inmunosupresor. - Google Patents

Uso de un compuesto inhibidor de esfingosina-1-fosfato (s1p) liasa derivado de imidazol -etiloxima,-hidrazida, -sulfonohidrazid o -carboxamida y un inmunosupresor para tratar o prevenir un trastorno inunologico o inflamatorio; y composicion farmaceutica que comprende dicho compuesto y un inmunosupresor.

Info

Publication number
CL2008002652A1
CL2008002652A1 CL2008002652A CL2008002652A CL2008002652A1 CL 2008002652 A1 CL2008002652 A1 CL 2008002652A1 CL 2008002652 A CL2008002652 A CL 2008002652A CL 2008002652 A CL2008002652 A CL 2008002652A CL 2008002652 A1 CL2008002652 A1 CL 2008002652A1
Authority
CL
Chile
Prior art keywords
immunosuppressant
immune
pharmaceutical composition
imidazole
sulfonohydrazid
Prior art date
Application number
CL2008002652A
Other languages
English (en)
Inventor
Oravecz Tamas
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39942679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002652(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CL2008002652A1 publication Critical patent/CL2008002652A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica que comprende compuestos derivados de imidazol y método para tratar, manejar o prevenir una enfermedad o trastorno inmunológico o inflamatorio.
CL2008002652A 2007-09-06 2008-09-05 Uso de un compuesto inhibidor de esfingosina-1-fosfato (s1p) liasa derivado de imidazol -etiloxima,-hidrazida, -sulfonohidrazid o -carboxamida y un inmunosupresor para tratar o prevenir un trastorno inunologico o inflamatorio; y composicion farmaceutica que comprende dicho compuesto y un inmunosupresor. CL2008002652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97041607P 2007-09-06 2007-09-06

Publications (1)

Publication Number Publication Date
CL2008002652A1 true CL2008002652A1 (es) 2009-03-20

Family

ID=39942679

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002652A CL2008002652A1 (es) 2007-09-06 2008-09-05 Uso de un compuesto inhibidor de esfingosina-1-fosfato (s1p) liasa derivado de imidazol -etiloxima,-hidrazida, -sulfonohidrazid o -carboxamida y un inmunosupresor para tratar o prevenir un trastorno inunologico o inflamatorio; y composicion farmaceutica que comprende dicho compuesto y un inmunosupresor.

Country Status (18)

Country Link
US (1) US7825150B2 (es)
EP (1) EP2182944A1 (es)
JP (1) JP2010538088A (es)
KR (1) KR20100061666A (es)
CN (1) CN101878030A (es)
AR (1) AR068229A1 (es)
AU (1) AU2008296212A1 (es)
BR (1) BRPI0816386A2 (es)
CA (1) CA2698713A1 (es)
CL (1) CL2008002652A1 (es)
IL (1) IL203988A (es)
MX (1) MX2010002559A (es)
NZ (1) NZ583278A (es)
RU (1) RU2010112997A (es)
TW (1) TW200920355A (es)
UY (1) UY31325A1 (es)
WO (1) WO2009032972A1 (es)
ZA (1) ZA201001055B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP5878015B2 (ja) * 2008-07-23 2016-03-08 ノバルティス アーゲー スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions
US8734852B2 (en) * 2011-11-30 2014-05-27 Manu Chaudhary Parenteral controlled release formulations of NSAID's
JP5725663B2 (ja) * 2011-12-28 2015-05-27 池田食研株式会社 酵素阻害剤
WO2021191336A1 (en) * 2020-03-27 2021-09-30 Ac Bioscience Sa A combination of flavonoids and sphingosine 1 phosphate lyase inhibitors for the treatment of lung inflammation
US20220395540A1 (en) * 2021-06-09 2022-12-15 Therapeutic Solutions International, Inc. Treatment of covid-19 lung injury using umbilical cord plasma based compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788548A (fr) * 1971-09-10 1973-03-08 Bayer Ag Nouveaux acides 2-imidazolyl-carbonyl-benzoiques, leurs esters et leur sels, leur procede de preparation et leur application comme regulateursde croissance des vegetaux
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
US4614662A (en) * 1985-08-26 1986-09-30 D. D. Williamson & Co., Inc. Fast cook-continuous process for production of ammonia caramel color
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
JPH06510781A (ja) 1991-09-26 1994-12-01 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ムピロシン関連の抗菌性、抗マイコプラスマ性化合物
GB9201391D0 (en) 1992-01-22 1992-03-11 Smithkline Beecham Plc Method of treatment
DE4205081A1 (de) 1992-02-20 1993-08-26 Bayer Ag 1-acyloxy-2-azolyl-ethane
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US5519040A (en) * 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
SE9401965D0 (sv) * 1994-06-07 1994-06-07 Astra Ab New compounds
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
ATE255564T1 (de) * 1994-09-26 2003-12-15 Shionogi & Co Imidazolderivat
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
ZA974811B (en) 1996-05-31 1997-12-30 Univ Wollongong Novel therapeutic compounds.
US6423527B1 (en) * 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
DK1188747T3 (da) * 1999-05-24 2006-01-23 Mitsubishi Pharma Corp Phenoxypropylaminforbindelser
DE10025672A1 (de) 2000-05-24 2001-11-29 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
DE10111936C1 (de) * 2001-03-13 2002-10-02 Wella Ag N-Heteroarylmethyl-m-phenylendiamin-Derivate enthaltende Haarfärbemittel sowie neue N-Heteroarylmethyl-m-phenylendiamin-Derivate
DE10130145A1 (de) * 2001-06-22 2003-01-02 Wella Ag Kationische Farbstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Färbemittel
PT1424330E (pt) * 2001-08-10 2011-12-22 Nippon Chemiphar Co Activador do receptor ä responsivo a proliferadores peroxissomais
AU2002323475B2 (en) * 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
US6692960B2 (en) 2001-09-28 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of sphingosine-1-phosphate lyase expression
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
MXPA06007054A (es) * 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
WO2005072412A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
MY146532A (en) * 2004-03-05 2012-08-15 Taisho Pharmaceutical Co Ltd Thiazole derivative
US8124111B2 (en) * 2005-06-10 2012-02-28 Children's Hospital & Research Center At Oakland Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) * 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
UY31013A1 (es) * 2007-04-12 2008-09-02 Lexicon Pharmaceuticals Inc Metodos para prepar compuestos basados en imidazol
JP2012500795A (ja) * 2008-08-22 2012-01-12 レクシコン ファーマシューティカルズ インコーポレイテッド 二環式のｓ１ｐリアーゼ阻害剤を含有する組合せ物

Also Published As

Publication number Publication date
JP2010538088A (ja) 2010-12-09
AU2008296212A1 (en) 2009-03-12
BRPI0816386A2 (pt) 2017-06-13
CN101878030A (zh) 2010-11-03
RU2010112997A (ru) 2011-10-20
WO2009032972A1 (en) 2009-03-12
US7825150B2 (en) 2010-11-02
CA2698713A1 (en) 2009-03-12
KR20100061666A (ko) 2010-06-08
MX2010002559A (es) 2010-06-01
EP2182944A1 (en) 2010-05-12
AR068229A1 (es) 2009-11-11
IL203988A (en) 2014-08-31
UY31325A1 (es) 2009-03-02
US20090068180A1 (en) 2009-03-12
NZ583278A (en) 2011-12-22
TW200920355A (en) 2009-05-16
AU2008296212A2 (en) 2010-03-25
ZA201001055B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CL2008002652A1 (es) Uso de un compuesto inhibidor de esfingosina-1-fosfato (s1p) liasa derivado de imidazol -etiloxima,-hidrazida, -sulfonohidrazid o -carboxamida y un inmunosupresor para tratar o prevenir un trastorno inunologico o inflamatorio; y composicion farmaceutica que comprende dicho compuesto y un inmunosupresor.
CL2012000024A1 (es) Composicion farmaceutica que comprende 100 a 2000 mg de metformina y 10 a 300 mg de un compuesto inhibidor de sglt-2 derivado de glucopiranosil fenil sustituidos, celulosa microcristalina, un aglutinante y croscaramelosa.
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
NI201100048A (es) Aminotriazolopiridinas y su uso como inhibidores de la cinasa.
UY32062A (es) Inhibidores de beta-secretasa
HK1131146A1 (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
ECSP11011014A (es) Compuestos de pirazolopirimidina inhibidores de jak y métodos
MX337906B (es) Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
BRPI0922135A2 (pt) composto de cromeno e derivado do mesmo.
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201100077A1 (ru) Производные пиримидина в качестве ингибиторов киназы
PE20080140A1 (es) DERIVADOS DE CINAMIDA MULTICICLICOS COMO INHIBIDORES DE ß AMILOIDE
MX2009009699A (es) Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa.
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
EA200970512A1 (ru) Лечение по поводу множественной миеломы
ECSP13012698A (es) Derivados de imidazol como inhibidores de la enzima pde10a
CL2008000029A1 (es) Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
CL2011000138A1 (es) Uso de compuestos acido 1-{4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxiimino)-etil-2-etil-bencil}-azetidin-3-carboxilico para la preparacion de un medicamento para prevenir, inhibir o tratar una condicion inflamatoria seleccionada de polimiositis o dermatomiositis.
EA201100078A1 (ru) Производные пиримидина в качестве ингибиторов киназы
CL2008001163A1 (es) Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.